Search by Drug Name or NDC

    NDC 00003-2187-13 ORENCIA 250 mg/15mL Details

    ORENCIA 250 mg/15mL

    ORENCIA is a INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by E.R. Squibb & Sons, L.L.C.. The primary component is ABATACEPT.

    Product Information

    NDC 00003-2187
    Product ID 0003-2187_ca83b90c-3ec0-4803-bf69-18c035bc41f0
    Associated GPIs 66400010002120
    GCN Sequence Number 060226
    GCN Sequence Number Description abatacept/maltose VIAL 250 MG INTRAVEN
    HIC3 S2Q
    HIC3 Description ANTINFLAMMATORY, SEL.COSTIM.MOD.,T-CELL INHIBITOR
    GCN 26306
    HICL Sequence Number 033411
    HICL Sequence Number Description ABATACEPT/MALTOSE
    Brand/Generic Brand
    Proprietary Name ORENCIA
    Proprietary Name Suffix n/a
    Non-Proprietary Name abatacept
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
    Route INTRAVENOUS
    Active Ingredient Strength 250
    Active Ingredient Units mg/15mL
    Substance Name ABATACEPT
    Labeler Name E.R. Squibb & Sons, L.L.C.
    Pharmaceutical Class Decreased Cytokine Activity [PE], Recombinant Fusion Proteins [CS], Selective T Cell Costimulation Modulator [EPC]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA125118
    Listing Certified Through 2024-12-31

    Package

    NDC 00003-2187-13 (00003218713)

    NDC Package Code 0003-2187-13
    Billing NDC 00003218713
    Package 1 VIAL, SINGLE-USE in 1 CARTON (0003-2187-13) / 15 mL in 1 VIAL, SINGLE-USE
    Marketing Start Date 2009-01-01
    NDC Exclude Flag N
    Pricing Information N/A